Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:Introduction (00:00)Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)Strategies to Prevent and Manage Hyperglycemia (27:02)Clinical Utility of Capivasertib for HR-Positive mBC (38:09)Mitigation and Management of Gastrointestinal Adverse Events (51:05)Management of Dermatologic Adverse Events (59:58)Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)Monitoring and Management of Cytopenias (1:21:23)CME information and select publications